Friday, 31 Oct 2025
  • Contact
  • Privacy Policy
  • Terms & Conditions
  • DMCA
logo logo
  • World
  • Politics
  • Crime
  • Economy
  • Tech & Science
  • Sports
  • Entertainment
  • More
    • Education
    • Celebrities
    • Culture and Arts
    • Environment
    • Health and Wellness
    • Lifestyle
  • 🔥
  • Trump
  • VIDEO
  • House
  • White
  • ScienceAlert
  • Trumps
  • Watch
  • man
  • Health
  • Season
Font ResizerAa
American FocusAmerican Focus
Search
  • World
  • Politics
  • Crime
  • Economy
  • Tech & Science
  • Sports
  • Entertainment
  • More
    • Education
    • Celebrities
    • Culture and Arts
    • Environment
    • Health and Wellness
    • Lifestyle
Follow US
© 2024 americanfocus.online – All Rights Reserved.
American Focus > Blog > Economy > Merck held talks to buy Swiss biotech MoonLake for more than $3bn
Economy

Merck held talks to buy Swiss biotech MoonLake for more than $3bn

Last updated: June 2, 2025 2:25 pm
Share
Merck held talks to buy Swiss biotech MoonLake for more than bn
SHARE

Unlock the Editor’s Digest for free

Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter.

Merck in Talks for More than $3bn Acquisition of Swiss Biotech MoonLake Immunotherapeutics

Merck, a US pharmaceutical company, has been in discussions regarding a potential acquisition of Swiss biotechnology group MoonLake Immunotherapeutics for over $3 billion. The New Jersey-based drugmaker made a nonbinding offer for MoonLake earlier this year, valuing the company at a premium to its current market value of $2.6 billion. While the initial offer was rebuffed, there is a possibility that talks could be reignited in the future.

MoonLake, founded in 2021 by former McKinsey partner Jorge Santos da Silva, is currently conducting phase-three trials for its lead drug, sonelokimab, as a treatment for hidradenitis suppurativa in adolescents and adults, as well as for psoriatic arthritis. With Morgan Stanley and Goldman Sachs advising MoonLake on the sale process, the company is well-positioned to attract potential buyers.

This move by Merck signals a return to the negotiation table following its acquisition of biotech EyeBio last year. With shareholder pressure mounting on Merck to make strategic acquisitions to boost investor confidence, the company is looking to replenish its drug pipeline amidst challenges such as the upcoming patent expiration of its $30 billion-a-year cancer drug Keytruda.

Merck’s Chief Executive, Rob Davis, has expressed the company’s commitment to pursuing deals despite market volatility. While there is no guarantee that a deal with MoonLake will materialize, the discussions underscore Merck’s strategic focus on expanding its portfolio through strategic acquisitions.

In a landscape where US healthcare dealmaking has slowed due to economic uncertainty and regulatory challenges, the pharmaceutical industry continues to see significant transactions. French drugmaker Sanofi recently announced a $9.5 billion acquisition of Blueprint Medicines, while Bristol Myers Squibb struck an up to $11 billion partnership deal with German drugmaker BioNTech for a cancer treatment in development.

See also  Global Plastic Treaty Talks Collapse in Busan

As the pharmaceutical industry navigates through evolving market dynamics, the potential acquisition of MoonLake by Merck represents a strategic move to strengthen its position in the biotechnology sector. With the negotiations ongoing, stakeholders will be closely monitoring developments to see how this deal could shape the future of both companies in the competitive healthcare landscape.

TAGGED:3bnBiotechBuyHeldMerckMoonLakeSwissTalks
Share This Article
Twitter Email Copy Link Print
Previous Article Black Death Plague Bacterium Became Less Fatal thanks to Just One Genetic Tweak Black Death Plague Bacterium Became Less Fatal thanks to Just One Genetic Tweak
Next Article Cruel NYC dog hoarder could face 1 year behind bars Cruel NYC dog hoarder could face 1 year behind bars
Leave a comment

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Popular Posts

Should I Protect My Wealth With Umbrella Insurance?

Umbrella insurance is a crucial secondary policy that provides additional coverage beyond your primary insurance.…

January 31, 2025

Olivia Rodrigo and Louis Partridge Bring Their Best Preppy Style to Wimbledon

The 2025 Wimbledon tournament has officially begun in London, and the star-studded guest list is…

July 2, 2025

Ernest Kingsley Jr. Travels The World

Hulu has unveiled the official trailer for its upcoming limited series, "Washington Black," featuring Ernest…

June 24, 2025

Turkey’s Queer Art Community Walks a Thin Line

Istanbul, known for its vibrant art scene, is facing challenges when it comes to showcasing…

November 18, 2024

OnePlus Pad Lite Review: Almost Brilliant Budget Tablet

The OnePlus Pad Lite is a budget-friendly Android tablet that aims to deliver a solid…

August 4, 2025

You Might Also Like

Market analysts react to Trump-Xi meet
Economy

Market analysts react to Trump-Xi meet

October 31, 2025
29 truck carrier files Chapter 11
Economy

29 truck carrier files Chapter 11

October 31, 2025
Trust Government Statistics, Not Government
Economy

Trust Government Statistics, Not Government

October 31, 2025
Jefferies Raises BP Price Target to 420 GBp, Maintains Hold Rating
Economy

Jefferies Raises BP Price Target to 420 GBp, Maintains Hold Rating

October 31, 2025
logo logo
Facebook Twitter Youtube

About US


Explore global affairs, political insights, and linguistic origins. Stay informed with our comprehensive coverage of world news, politics, and Lifestyle.

Top Categories
  • Crime
  • Environment
  • Sports
  • Tech and Science
Usefull Links
  • Contact
  • Privacy Policy
  • Terms & Conditions
  • DMCA

© 2024 americanfocus.online –  All Rights Reserved.

Welcome Back!

Sign in to your account

Lost your password?